Repligen Corporation announced the opening of its third Training & Innovation Center (RTIC) in Breda, Netherlands, on April 17, 2026, following the facility’s official opening on April 15, 2026. The new center is situated within the company’s OPUS® Pre‑packed Chromatography Columns manufacturing site and is designed to give customers hands‑on experience with Repligen’s bioprocessing solutions.
The Breda RTIC features product exhibits, purpose‑built demonstration areas, and workshop spaces that allow technical teams and customers to test ATF perfusion devices, OPUS® chromatography columns, and PATsmart analytical solutions in a real‑world setting. The facility’s layout emphasizes interactive learning, with dedicated zones for each product line and a collaborative space for joint problem‑solving sessions.
By adding a European hub, Repligen expands its global customer‑support network, complementing existing centers in Waltham, Massachusetts, and Tokyo, Japan. The move underscores the company’s strategy to bring training and support closer to its biopharma and CDMO clients, aiming to accelerate adoption of its expanding portfolio across the bioprocessing value chain.
"We are excited to open our third RTIC in Breda. The center provides a site for workshops and hands‑on training for our technical teams and customers, while also highlighting our increasingly broad and diversified portfolio and end‑to‑end bioprocessing capabilities," said Olivier Loeillot, President and CEO of Repligen.
Repligen operates in the life‑sciences sector, focusing on bioprocessing technology leadership. The new center reinforces the company’s commitment to customer proximity and education, positioning it to strengthen relationships with key partners and support the growing demand for efficient, scalable biomanufacturing solutions across its global manufacturing footprint.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.